[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Chemotherapy Induced Peripheral Neuropathy Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 60 pages | ID: C960E2CCA21EN
VPAResearch

US$ 700.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Chemotherapy Induced Peripheral Neuropathy ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Chemotherapy Induced Peripheral Neuropathy disease clinical trials. The research work analyzes the ongoing Chemotherapy Induced Peripheral Neuropathy clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Chemotherapy Induced Peripheral Neuropathy treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Chemotherapy Induced Peripheral Neuropathy clinical trials.

Scope of the Report-
  • Ongoing Chemotherapy Induced Peripheral Neuropathy clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Chemotherapy Induced Peripheral Neuropathy
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Chemotherapy Induced Peripheral Neuropathy clinical trials
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Chemotherapy Induced Peripheral Neuropathy Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials by Phase
3.2 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials by Type
3.3 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Chemotherapy Induced Peripheral Neuropathy Trials
4.2 Top 10 Countries conducting Chemotherapy Induced Peripheral Neuropathy Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials by Sponsor Type
5.2 Chemotherapy Induced Peripheral Neuropathy Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Chemotherapy Induced Peripheral Neuropathy Trials by year
6.2 Subjects Recruited for Chemotherapy Induced Peripheral Neuropathy Trials by Phase
6.3 Subjects Recruited for Chemotherapy Induced Peripheral Neuropathy Trials by Trial Type
6.4 Subjects Recruited for Chemotherapy Induced Peripheral Neuropathy Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials- Phase
7.2 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials- Phase
7.3 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials- Phase
7.4 Ongoing Chemotherapy Induced Peripheral Neuropathy Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

LIST OF FIGURES

Figure 1: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Country
Figure 2: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Phase of Development, 2018
Figure 3: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Status, 2018
Figure 4: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Type, 2018
Figure 5: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials Split by Region, 2000-2018
Figure 6: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Type of Economy, 2018
Figure 7: Chemotherapy Induced Peripheral Neuropathy- Enrolment by Phase, 2018
Figure 8: Chemotherapy Induced Peripheral Neuropathy- Enrolment by Trial Type, 2018
Figure 9: Chemotherapy Induced Peripheral Neuropathy- Enrolment by Recruitment Status, 2018
Figure 10: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Sponsor Type, 2018
Figure 11: Chemotherapy Induced Peripheral Neuropathy- Enrolment by Type of Sponsors
Figure 12: Chemotherapy Induced Peripheral Neuropathy- Enrolment by Leading Sponsors

LIST OF TABLES

Table 1: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Sponsor Type, 2018
Table 2: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Economy Type, 2018
Table 3: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials by Region, 2018
Table 4: Chemotherapy Induced Peripheral Neuropathy- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Chemotherapy Induced Peripheral Neuropathy- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Chemotherapy Induced Peripheral Neuropathy- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Chemotherapy Induced Peripheral Neuropathy- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Chemotherapy Induced Peripheral Neuropathy- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Chemotherapy Induced Peripheral Neuropathy- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company


More Publications